A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of TX-12-004-HR in Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy (VVA)
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2016
At a glance
- Drugs Estradiol (Primary)
- Indications Atrophic vaginitis; Vulvovaginitis
- Focus Therapeutic Use
- Sponsors TherapeuticsMD
- 22 Sep 2016 According to a TherapeuticsMD media release, data of this trial will be presented at annual meetings of the International Menopause Society (IMS) and the North American Menopause Society (NAMS), 2016.
- 22 Oct 2013 Status changed from recruiting to completed.
- 12 Aug 2013 Status changed from planning to recruiting, according to a TherapeuticsMD media release; 44% of patients have been enrolled to date.